By Cocer Peptides 
22 days ago
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
Overview
Thymosin Alpha-1 (Tα1) is a highly conserved polypeptide composed of 28 amino acids that plays a critical role in immune regulation within the body. It was initially isolated from thymus extracts and has gained prominence in the field of immunodeficiency due to its unique immune-modulating properties. Immune deficiency refers to abnormalities in the function of the immune system, leading to reduced ability to resist pathogen invasion and eliminate abnormal cells. This condition can be caused by various factors, including congenital genetic factors and acquired factors such as infections, drug use, and malignant tumors. Patients with immune deficiency face a higher risk of infection, and infections often result in more severe conditions and increased treatment difficulties.
Figure 1 Immunoregulation of Tα1 and action mechanisms.
In-depth analysis of immunoregulatory mechanisms
Regulation of T cell maturation and differentiation: Tα1 plays a crucial role in regulating the maturation and differentiation of T cells. In the thymus, Tα1 can stimulate the differentiation of thymic cells, promoting their transformation from progenitor cells to mature T cells. This process involves the activation of multiple signaling pathways, such as binding to specific receptors on the surface of T cells, activating intracellular signal transduction cascades, and inducing changes in the expression of relevant transcription factors, thereby regulating the expression of genes related to T cell development. Mature T cells play a central role in cellular immunity within the immune system, including the recognition and killing of virus-infected cells and tumor cells. Tα1 enhances T cell maturation and differentiation, thereby establishing a stronger cellular immune defense for the body.
Activation of innate immune cells: Tα1 also has an activating effect on innate immune cells. Macrophages, as important members of the innate immune system, exhibit significantly enhanced phagocytic capacity under the influence of Tα1. Tα1 activates Toll-like receptors (TLRs) on the surface of macrophages, initiating downstream signaling pathways that prompt macrophages to secrete various cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and others. These cytokines not only enhance the immune activity of macrophages themselves but also recruit and activate other immune cells, triggering a broader immune response. Tα1 also enhances the cytotoxic activity of natural killer (NK) cells, enabling them to more effectively recognize and kill virus-infected cells or tumor cells, thereby establishing the first line of defense for the body's immune defense.
Regulating cytokine network balance: Cytokines act as messengers in the immune system, regulating interactions between immune cells and the intensity of immune responses. Tα1 can precisely regulate the balance of the cytokine network. In an immunosuppressed state, Tα1 promotes the secretion of Th1-type cytokines (such as interferon-γ, IFN-γ), enhancing cellular immune function. In cases of immune overactivation, Tα1 can inhibit the excessive production of certain pro-inflammatory cytokines (such as interleukin-6, IL-6), reducing the damage caused by inflammatory responses to the body. This bidirectional regulatory effect allows Tα1 to flexibly adjust the intensity and direction of immune responses according to changes in the body's immune state, maintaining immune system homeostasis.
Induction of immune tolerance-related pathways: Tα1 can activate the tryptophan catabolic pathway associated with immune tolerance by regulating the activity of the immune regulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO catalyzes tryptophan metabolism, leading to reduced tryptophan levels in the cellular microenvironment, thereby inhibiting T cell proliferation and activation, inducing immune tolerance. In conditions such as autoimmune diseases or transplant rejection reactions, Tα1 helps break the vicious cycle of immune overactivation by activating this pathway, alleviating immune-related pathological damage, and creating a relatively stable immune microenvironment for the body.
Role in immune deficiency-related diseases
Congenital immune deficiency disorders: Congenital immune deficiency disorders are caused by genetic factors leading to incomplete development or dysfunction of the immune system. For some patients with congenital T cell immunodeficiency, Tα1 therapy can significantly improve T cell function. In cases of congenital immunodeficiency associated with thymic hypoplasia, Tα1 promotes the differentiation and maturation of thymic cells, increases the number of mature T cells in peripheral blood, enhances cellular immune function, and enhances the patient's resistance to pathogens, reducing the frequency and severity of infections. After a period of Tα1 therapy, the proportion of T cell subsets in the patient's body gradually returns to normal, immunoglobulin levels increase, and clinical symptoms improve significantly.
Acquired Immunodeficiency Syndrome (AIDS): AIDS is caused by infection with the human immunodeficiency virus (HIV), which primarily targets CD4+ T lymphocytes, leading to severe damage to the immune system. Tα1 plays a multifaceted role in AIDS treatment. It can enhance immune function in HIV-infected individuals, increase the number and activity of CD4+ T cells, and partially restore the body's immune defense capabilities. Studies have shown that when Tα1 is added to highly active antiretroviral therapy (HAART), it can lead to a more significant increase in CD4+ T cell counts and better immune reconstitution outcomes. Tα1 can also regulate cytokine balance in patients, reduce inflammatory responses, alleviate chronic inflammatory damage caused by HIV infection and immune activation, and improve patients' quality of life and survival rates.
Figure 2 Change in sjTREC levels (copies/µ1 blood) in PBMCs from study patients. Error bars denote 95% confidence intervals and P value calculated using the Mann–Whitney U-test.
Immune deficiency associated with malignant tumors: Patients with tumors often experience impaired immune function during disease progression and after receiving treatments such as chemotherapy and radiotherapy. Tα1 has a significant ameliorative effect in this regard. It enhances the body's antitumor immune response by activating immune cells such as T cells and NK cells, thereby improving their ability to recognize and kill tumor cells. Tα1 can mitigate the immunosuppressive effects of chemotherapy and radiotherapy and promote the recovery of immune function. For patients with non-small cell lung cancer and liver cancer who have undergone surgical resection, the use of Tα1 in adjuvant therapy can significantly improve overall survival. For patients with locally advanced, unresectable non-small cell lung cancer, Tα1 can significantly reduce adverse reactions such as lymphocytopenia and pneumonia caused by chemoradiotherapy, and there is a trend toward improved overall survival.
Infection-related immune deficiency: In severe infections, such as severe sepsis, the body often enters an immunosuppressed state, making it difficult for patients to resist primary bacterial infections, reducing resistance to secondary hospital-acquired infections, and increasing the risk of viral infection recurrence. Tα1 has been proven to restore immune function and help reduce mortality in patients with severe sepsis. It achieves this by activating innate immune cells and regulating T cell function to enhance the body's ability to clear pathogens, while modulating the cytokine network to mitigate the damage caused by excessive inflammatory responses, thereby improving patient outcomes.
Current clinical applications and future prospects
Current clinical application: Tα1 is widely used in the treatment of cancer patients and those with severe infections, and was urgently deployed as an immunomodulator during the severe acute respiratory syndrome (SARS) and COVID-19 pandemics. In clinical practice, Tα1 is typically administered via subcutaneous injection, demonstrating good tolerability, with most studies reporting only local irritation at the injection site.
Combination with Other Treatment Modalities: To further enhance therapeutic efficacy, Tα1 is often used in combination with other treatment modalities. In oncology, Tα1 demonstrates potent synergistic effects when combined with chemotherapy agents. It enhances the antitumor activity of chemotherapy drugs while mitigating their immunosuppressive effects, thereby improving patients' quality of life. In cancer treatment with immune checkpoint inhibitors (ICIs), Tα1 also has potential synergistic effects. Tα1 can reverse macrophage M2 polarization by activating the TLR7/SHIP1 axis, enhance antitumor immunity, and transform “cold tumors” into “hot tumors,” thereby improving the efficacy of ICIs. Tα1 may also play a protective role in alleviating immune-related adverse reactions such as colitis caused by ICIs.
Conclusion
As a novel peptide therapy, Prostamax demonstrates advantages in the field of prostate health. From its unique mechanism of action to its significant effects in improving inflammation, maintaining tissue structure, and enhancing reproductive function, as well as its diverse application pathways in clinical treatment, preventive care, and combined therapy, it contributes to the treatment and prevention of prostate diseases.
References
[1] Bellet M M, Renga G, Pariano M, et al. Special Thymosin Issue COVID-19 and beyond: reassessing the role of thymosin alpha1 in lung infections, 2023[C]. https://api.semanticscholar.org/CorpusID:267839769
[2] Wei Y, Zhang Y, Li P, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications[J]. International Immunopharmacology, 2023,117:109744.DOI:10.1016/j.intimp.2023.109744.
[3] Shang W, Zhang B, Ren Y, et al. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes[J]. International Immunopharmacology, 2023,114:109584.DOI:10.1016/j.intimp.2022.109584.
[4] Stincardini C, Renga G, Villella V, et al. Cellular proteostasis: a new twist in the action of thymosin α1[J]. Expert Opinion On Biological Therapy, 2018,18(sup1):43-48.DOI:10.1080/14712598.2018.1484103.
[5] Li J, Liu C H, Wang F S. Thymosin alpha 1: Biological activities, applications and genetic engineering production[J]. Peptides, 2010,31(11):2151-2158.DOI:https://doi.org/10.1016/j.peptides.2010.07.026.
[6] Chadwick D, Pido-Lopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy[J]. Clinical and Experimental Immunology, 2003,134(3):477-481.DOI:10.1111/j.1365-2249.2003.02331.x.
[7] Ancell C D, Phipps J, Young L. Thymosin alpha-1[J]. American Journal of Health-System Pharmacy, 2001,58(10):879-885.DOI:10.1093/ajhp/58.10.879.
Product available for research use only:
